

Table 1. Summary data on dose-finding study of 2,6-Bis(1,1-dimethylethyl)-4-ethylphenol  
[ Non-activation method : -S9]

Compound	Dose (µg/plate)	Revertant colonies per plate [Mean ± S.D.]												
		TA100	TA1535	WP2uvrA	TA98	TA1537								
2,6-Bis(1,1-dimethylethyl)-4-ethylphenol	0 a)	129 [ 130 ± 6]	14 [ 15 ± 2]	18 [ 23 ± 5]	21 [ 22 ± 2]	24 [ 22 ± 2]	21 [ 21 ± 2]	21 [ 21 ± 2]	21 [ 21 ± 2]	21 [ 21 ± 2]	21 [ 21 ± 2]	8 [ 9 ± 2]	12 [ 12 ± 2]	8 [ 8 ± 2]
	8.19	116 [ 117 ± 2]	14 [ 13 ± 2]	14 [ 22 ± 3]	20 [ 22 ± 3]	25 [ 15 ± 3]	18 [ 15 ± 3]	13 [ 15 ± 3]	13 [ 15 ± 3]	13 [ 15 ± 3]	13 [ 15 ± 3]	5 [ 6 ± 1]	7 [ 6 ± 1]	6 [ 6 ± 1]
	20.5	137 [ 127 ± 9]	7 [ 9 ± 3]	13 [ 24 ± 3]	22 [ 24 ± 3]	28 [ 16 ± 3]	17 [ 16 ± 3]	14 [ 16 ± 3]	14 [ 16 ± 3]	14 [ 16 ± 3]	14 [ 16 ± 3]	6 [ 7 ± 3]	5 [ 5 ± 3]	10 [ 10 ± 3]
	51.2	111 [ 115 ± 4]	16 [ 11 ± 4]	9 [ 21 ± 4]	25 [ 21 ± 4]	20 [ 16 ± 4]	17 [ 16 ± 4]	16 [ 16 ± 4]	16 [ 16 ± 4]	16 [ 16 ± 4]	16 [ 16 ± 4]	9 [ 8 ± 4]	6 [ 8 ± 4]	9 [ 9 ± 4]
	128	118 [ 126 ± 7]	15 [ 14 ± 2]	12 [ 24 ± 2]	24 [ 24 ± 2]	26 [ 18 ± 2]	18* [ 18 ± 2]	15* [ 18 ± 2]	20* [ 18 ± 2]	20* [ 18 ± 2]	20* [ 18 ± 2]	6* [ 7 ± 2]	8* [ 7 ± 2]	8* [ 7 ± 2]
	320	107 [ 107 ± 1]	11 [ 13 ± 2]	15 [ 29 ± 5]	31 [ 29 ± 5]	23 [ 22 ± 5]	21* [ 22 ± 5]	24* [ 22 ± 5]	20* [ 22 ± 5]	20* [ 22 ± 5]	20* [ 22 ± 5]	12* [ 11 ± 5]	10* [ 11 ± 5]	10* [ 11 ± 5]
	800	126 [ 118 ± 17]	15 [ 14 ± 2]	12 [ 27 ± 4]	30 [ 27 ± 4]	22 [ 22 ± 4]	20* [ 22 ± 4]	21* [ 22 ± 4]	24* [ 22 ± 4]	24* [ 22 ± 4]	24* [ 22 ± 4]	7* [ 7 ± 4]	8* [ 7 ± 4]	5* [ 5 ± 4]
	2000 +	109 [ 111 ± 8]	13 [ 11 ± 2]	11 [ 22 ± 2]	20 [ 22 ± 2]	24 [ 20 ± 2]	17* [ 20 ± 2]	22* [ 20 ± 2]	20* [ 20 ± 2]	20* [ 20 ± 2]	20* [ 20 ± 2]	7* [ 7 ± 2]	8* [ 7 ± 2]	5* [ 5 ± 2]
	5000 +	101 [ 101 ± 2]	10 [ 8 ± 2]	8 [ 24 ± 2]	23 [ 24 ± 2]	22 [ 15 ± 2]	17* [ 15 ± 2]	16* [ 15 ± 2]	13* [ 15 ± 2]	13* [ 15 ± 2]	13* [ 15 ± 2]	5* [ 3 ± 2]	2* [ 3 ± 2]	3* [ 2 ± 2]
	Positive control	911 [ 897 ± 13]	886 b)	604 [ 582 ± 24]	557 [ 156 ± 8]	158 [ 665 ± 15]	147 b)	673 [ 665 ± 15]	647 d)	647 d)	647 d)	248 [ 259 ± 19]	247 [ 259 ± 19]	281 e)

a): Negative control (Dimethyl sulfoxide, 100 µL/plate)  
b): AF-2; 2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide, 0.01 µg/plate c): NaN<sub>3</sub>; Sodium azide, 0.5 µg/plate  
d): AF-2, 0.1 µg/plate e): 9-AA; 9-Aminoacridine hydrochloride, 80 µg/plate  
\* : Growth inhibition was observed.  
+ : Visible precipitation was observed at the end of exposure period.

Table 2. Summary data on dose-finding study of 2,6-Bis(1,1-dimethylethyl)-4-ethylphenol  
 [Activation method : +S9] Exp. No. 9048 (115-199)

Compound	Dose (µg/plate)	Revertant colonies per plate [Mean ± S.D.]									
		TA100	TA1535	WP2uvrA	TA98	TA1537					
2,6-Bis(1,1-dimethylethyl)-4-ethylphenol	0 a)	129 [ 132 ± 4]	136 [ 13 ± 2]	132 [ 27 ± 3]	28 [ 29 ± 2]	29 [ 24 ± 2]	31 [ 29 ± 2]	27 [ 24 ± 2]	28 [ 24 ± 2]	23 [ 24 ± 2]	23
	8.19	131 [ 135 ± 9]	145 [ 16 ± 3]	23 [ 24 ± 3]	28 [ 26 ± 2]	22 [ 17 ± 2]	28 [ 26 ± 2]	24 [ 17 ± 2]	26 [ 17 ± 2]	14 [ 17 ± 2]	14
	20.5	131 [ 137 ± 5]	141 [ 15 ± 1]	31 [ 28 ± 3]	38 [ 35 ± 3]	34 [ 16 ± 1]	33 [ 35 ± 3]	38 [ 16 ± 1]	34 [ 16 ± 1]	15 [ 16 ± 1]	15
	51.2	120 [ 125 ± 4]	128 [ 12 ± 2]	25 [ 23 ± 2]	30 [ 26 ± 5]	28 [ 16 ± 3]	21 [ 26 ± 5]	30 [ 16 ± 3]	28 [ 16 ± 3]	19 [ 16 ± 3]	19
	128	112 [ 108 ± 4]	106 [ 8 ± 1]	28 [ 24 ± 4]	32 [ 29 ± 3]	26 [ 15 ± 1]	28 [ 29 ± 3]	32 [ 15 ± 1]	26 [ 15 ± 1]	16 [ 15 ± 1]	16
	320	106 [ 106 ± 2]	105 [ 9 ± 1]	23 [ 23 ± 1]	24 [ 26 ± 3]	17 [ 16 ± 2]	29 [ 26 ± 3]	24 [ 16 ± 2]	26 [ 16 ± 2]	17 [ 16 ± 2]	17
	800	86 [ 89 ± 5]	86 [ 13 ± 2]	24 [ 24 ± 1]	28 [ 28 ± 1]	16 [ 14 ± 2]	28 [ 28 ± 1]	28 [ 14 ± 2]	27 [ 14 ± 2]	12 [ 14 ± 2]	16
	2000 +	89 [ 91 ± 7]	85 [ 11 ± 2]	26 [ 23 ± 3]	29 [ 26 ± 3]	11 [ 13 ± 3]	27 [ 26 ± 3]	29 [ 13 ± 3]	23 [ 13 ± 3]	11 [ 13 ± 3]	11
	5000 +	76 [ 83 ± 6]	87 [ 12 ± 3]	20 [ 22 ± 2]	21 [ 19 ± 2]	5 [ 5 ± 1]	19 [ 19 ± 2]	21 [ 5 ± 1]	18 [ 5 ± 1]	4 [ 5 ± 1]	6
	Positive control		1013 [ 1054 ± 44]	1048 [ 332 ± 10]	1101 [ 335 c) ± 10]	498 [ 501 ± 8]	510 [ 494 d) ± 8]	367 [ 377 ± 10]	378 [ 378 e) ± 10]	180 [ 185 ± 10]	179 [ 196 c) ± 10]

a) : Negative control (Dimethyl sulfoxide, 100 µL/plate)  
 b) : 2-AA; 2-Aminanthracene, 1 µg/plate c) : 2-AA, 2 µg/plate d) : 2-AA, 10 µg/plate e) : 2-AA, 0.5 µg/plate  
 + : Visible precipitation was observed at the end of exposure period.

Table 3. Summary data on dose-finding study of 2,6-Bis(1,1-dimethylethyl)-4-ethylphenol (Additional study)  
 [Non-activation method : -S9] Exp. No. 9048 (115-199)

Compound	Dose ( $\mu\text{g}/\text{plate}$ )	Revertant colonies per plate [ Mean $\pm$ S.D.]															
		TA100	TA1535	WP2uvrA	TA98	TA1537	TA100	TA1535	WP2uvrA	TA98	TA1537						
2,6-Bis(1,1-dimethylethyl)-4-ethylphenol	0 a)	122	125	132	16	17	14	27	34	24	19	22	22	22	9	14	11
		[ 126	$\pm$	5]	[ 16	$\pm$	2]	[ 28	$\pm$	5]	[ 21	$\pm$	2]	[ 11	$\pm$	3]	
		1.31	126	130	132	15	12	15	22	25	27	19	14	19	14	9	11
		[ 129	$\pm$	3]	[ 14	$\pm$	2]	[ 25	$\pm$	3]	[ 17	$\pm$	3]	[ 11	$\pm$	2]	
		121	130	115	15	12	18	21	20	21	18	24	16	16	9	7	10
		[ 122	$\pm$	8]	[ 15	$\pm$	3]	[ 21	$\pm$	1]	[ 19	$\pm$	4]	[ 9	$\pm$	2]	
		8.19	114	104	102	13	14	12	26	26	27	15	19	20	11	11	8
		[ 107	$\pm$	6]	[ 13	$\pm$	1]	[ 26	$\pm$	1]	[ 18	$\pm$	3]	[ 10	$\pm$	2]	
		20.5	113	113	123	17	18	14	27	24	28	12	12	19	12	9	8
		[ 116	$\pm$	6]	[ 16	$\pm$	2]	[ 26	$\pm$	2]	[ 14	$\pm$	4]	[ 10	$\pm$	2]	
		51.2	100	106	105	15	14	15	23	28	26	14	17	13	10	10	6
		[ 104	$\pm$	3]	[ 15	$\pm$	1]	[ 26	$\pm$	3]	[ 15	$\pm$	2]	[ 9	$\pm$	2]	
	128	106	113	103	12	16	8	18	21	20	17	20	18	12	11	9	
	[ 107	$\pm$	5]	[ 12	$\pm$	4]	[ 20	$\pm$	2]	[ 18	$\pm$	2]	[ 11	$\pm$	2]		
	320	99*	95*	96*	10	13	12	15	20	20	16*	17*	21*	8*	12*	8*	
	[ 97	$\pm$	2]	[ 12	$\pm$	2]	[ 18	$\pm$	3]	[ 18	$\pm$	3]	[ 9	$\pm$	2]		

a): Negative control(Dimethyl sulfoxide, 100  $\mu\text{L}/\text{plate}$ )

\* : Growth inhibition was observed.

Table 3. Continued

Compound	Dose (µg/plate)	Revertant colonies per plate [Mean ± S.D.]									
		TA100	TA1535	WP2uvza	TA98	TA1537	TA100	TA1535	WP2uvza	TA98	TA1537
2,6-Bis(1,1-dimethylethyl)-4-ethylphenol	800	99* 91* 102*	13 10 9	25 26 24	15* 14* 17*	9* 9* 12*	[ 97 ± 6]	[ 11 ± 2]	[ 25 ± 1]	[ 15 ± 2]	[ 10 ± 2]
		102* 95* 103*	11 13 12	24 23 21	19* 14* 18*	8* 9* 6*	[ 100 ± 4]	[ 12 ± 1]	[ 23 ± 2]	[ 17 ± 3]	[ 8 ± 2]
Positive control	5000 +	97* 98* 91*	9 12 10	18 25 20	10* 9* 13*	5* 5* 4*	[ 95 ± 4]	[ 10 ± 2]	[ 21 ± 4]	[ 11 ± 2]	[ 5 ± 1]
		830 726 767 b)	516 592 553 c)	150 164 142 b)	679 700 649 d)	167 239 224 e)	[ 774 ± 52]	[ 554 ± 38]	[ 152 ± 11]	[ 676 ± 26]	[ 210 ± 38]

b): AF-2; 2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide, 0.01 µg/plate c): NaN<sub>3</sub>; Sodium azide, 0.5 µg/plate

d): AF-2, 0.1 µg/plate e): 9-AA; 9-Aminoacridine hydrochloride, 80 µg/plate

\* : Growth inhibition was observed.

+ : Visible precipitation was observed at the end of exposure period.

Table 4. Summary data on bacterial reverse mutation test of 2,6-Bis(1,1-dimethylethyl)-4-ethylphenol  
 [Non-activation method : -S9] Exp. No. 9048 (115-199)

Compound	Dose (µg/plate)	Revertant colonies per plate [ Mean ± S.D.]														
		TA100			TA1535			WP2uvrA			TA98			TA1537		
2,6-Bis(1,1-dimethylethyl)-4-ethylphenol	0 a)	125 [ 124 ± 6]	130 [ 118 ± 6]	118 [ 15 ± 4]	15 [ 4]	19 [ 15 ± 4]	21 [ 25 ± 6]	21 [ 25 ± 6]	32 [ 25 ± 6]	23 [ 23 ± 6]	25 [ 22 ± 6]	19 [ 22 ± 6]	21 [ 21 ± 6]	10 [ 9 ± 1]	9 [ 9 ± 1]	9 [ 9 ± 1]
	9.77	108 [ 111 ± 3]	112 [ 114 ± 3]	114 [ 114 ± 3]							23 [ 22 ± 2]	24 [ 24 ± 2]	20 [ 20 ± 2]	8 [ 8 ± 2]	12 [ 12 ± 2]	8 [ 8 ± 2]
	19.5	103 [ 106 ± 12]	119 [ 119 ± 12]	96 [ 96 ± 12]						26 [ 20 ± 7]	22 [ 22 ± 7]	13 [ 13 ± 7]	9 [ 9 ± 2]	10 [ 10 ± 2]	7 [ 7 ± 2]	7 [ 7 ± 2]
	39.1	110 [ 102 ± 14]	110 [ 110 ± 14]	85 [ 85 ± 14]						21 [ 23 ± 3]	27 [ 27 ± 3]	22 [ 22 ± 3]	12 [ 12 ± 2]	8 [ 8 ± 2]	9 [ 9 ± 2]	9 [ 9 ± 2]
	78.1	111 [ 103 ± 7]	102 [ 102 ± 7]	97 [ 97 ± 7]						25 [ 26 ± 4]	22 [ 22 ± 4]	30 [ 30 ± 4]	9 [ 9 ± 1]	8 [ 8 ± 1]	8 [ 8 ± 1]	1 [ 1 ± 1]
	156	92 [ 100 ± 7]	105 [ 105 ± 7]	102 [ 102 ± 7]	8 [ 11 ± 3]	13 [ 13 ± 3]	13 [ 13 ± 3]	22 [ 23 ± 4]	19 [ 19 ± 4]	27 [ 27 ± 4]	14 [ 18 ± 6]	15 [ 15 ± 6]	24 [ 24 ± 6]	7* [ 7 ± 1]	7* [ 7 ± 1]	6* [ 6 ± 1]
	313	83 [ 97 ± 12]	103 [ 103 ± 12]	104 [ 104 ± 12]	14 [ 11 ± 4]	13 [ 13 ± 4]	7 [ 7 ± 4]	23 [ 24 ± 4]	28 [ 28 ± 4]	21 [ 21 ± 4]	17 [ 17 ± 4]	15 [ 15 ± 4]	20 [ 20 ± 4]	9* [ 9 ± 2]	5* [ 5 ± 2]	7* [ 7 ± 2]
	625	88* [ 101 ± 12]	103* [ 103 ± 12]	111* [ 111 ± 12]	8 [ 10 ± 4]	15 [ 15 ± 4]	8 [ 8 ± 4]	28 [ 25 ± 3]	25 [ 25 ± 3]	22 [ 22 ± 3]	23* [ 24 ± 2]	26* [ 26 ± 2]	22* [ 22 ± 2]	5* [ 5 ± 2]	7* [ 7 ± 2]	8* [ 8 ± 2]

a) : Negative control (Dimethyl sulfoxide, 100 µL/plate)  
 \* : Growth inhibition was observed.

Table 4. Continued

Compound	Dose (µg/plate)	Revertant colonies per plate [ Mean ± S.D.]														
		TA100	TA1535	WP2uvrA	TA98	TA1537										
2,6-Bis(1,1-dimethylethyl)-4-ethylphenol	1250 +	16	14	15	25	34	22									
		[ 15 ± 1 ]	[ 1 ]	[ 27 ± 6 ]												
	2500 +	8	11	9	21	12	23									
		[ 9 ± 2 ]	[ 2 ]	[ 19 ± 6 ]												
	5000 +	12	11	12	22	17	19									
		[ 12 ± 1 ]	[ 1 ]	[ 19 ± 3 ]												
Positive control		493	510	494 b)	565	570	592 c)	151	137	135 b)	713	673	658 d)	272	272	219 e)
		[ 499 ± 10 ]	[ 576 ± 14 ]	[ 141 ± 9 ]	[ 681 ± 28 ]	[ 254 ± 31 ]										

b): AF-2; 2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide, 0.01 µg/plate c): NaN<sub>3</sub>; Sodium azide, 0.5 µg/plate

d): AF-2, 0.1 µg/plate e): 9-AA; 9-Aminoacridine hydrochloride, 80 µg/plate

+ : Visible precipitation was observed at the end of exposure period.

Table 5. Summary data on bacterial reverse mutation test of 2,6-Bis(1,1-dimethylethyl)-4-ethylphenol  
 [Activation method : +S9]

Compound	Dose (µg/plate)	Revertant colonies per plate [Mean ± S.D.]									
		TA100	TA1535	WP2uvrA	TA98	TA1537					
2,6-Bis(1,1-dimethylethyl)-4-ethylphenol	0 a)	117 [ 119 ± 7]	127 [ 12 ± 7]	114 [ 12 ± 4]	16 [ 12 ± 4]	10 [ 26 ± 3]	28 [ 26 ± 3]	23 [ 27 ± 7]	26 [ 25 ± 7]	35 [ 24 ± 3]	19
	156	98 [ 101 ± 3]	101 [ 104 ± 3]	104 [ 11 ± 2]	9 [ 11 ± 2]	13 [ 22 ± 2]	23 [ 22 ± 2]	20 [ 28 ± 4]	25 [ 22 ± 3]	28 [ 25 ± 3]	19
	313	100 [ 103 ± 3]	103 [ 106 ± 3]	106 [ 14 ± 5]	17 [ 14 ± 5]	16 [ 23 ± 7]	30 [ 23 ± 7]	24 [ 26 ± 3]	16 [ 20 ± 5]	25 [ 17 ± 3]	18
	625	99 [ 100 ± 4]	97 [ 104 ± 4]	104 [ 12 ± 4]	16 [ 12 ± 4]	8 [ 21 ± 10]	17 [ 21 ± 10]	33 [ 27 ± 5]	14 [ 19 ± 3]	22 [ 21 ± 3]	20
	1250 +	87 [ 87 ± 7]	94 [ 80 ± 7]	80 [ 15 ± 2]	16 [ 15 ± 2]	12 [ 20 ± 4]	18 [ 20 ± 4]	17 [ 29 ± 5]	24 [ 13 ± 3]	26 [ 14 ± 3]	17
2500 +	90 [ 87 ± 4]	88 [ 83 ± 4]	83 [ 9 ± 3]	12 [ 9 ± 3]	10 [ 18 ± 3]	21 [ 18 ± 3]	18 [ 22 ± 2]	15 [ 19 ± 2]	23 [ 8 ± 2]	6	
5000 +	86 [ 81 ± 7]	73 [ 73 ± 7]	85 [ 8 ± 2]	7 [ 8 ± 2]	10 [ 18 ± 2]	18 [ 18 ± 2]	16 [ 21 ± 2]	20 [ 21 ± 2]	21 [ 9 ± 2]	6	
Positive control		939 [ 912 ± 61]	842 [ 954 b)	954 b)	371 [ 349 ± 28]	318 [ 534 ± 45]	359 c)	561 d)	406 [ 394 ± 28]	120 [ 137 ± 16]	142 c)

a): Negative control (Dimethyl sulfoxide, 100 µL/plate)

b): 2-AA; 2-Aminanthracene, 1 µg/plate c): 2-AA, 2 µg/plate d): 2-AA, 10 µg/plate e): 2-AA, 0.5 µg/plate

+ : Visible precipitation was observed at the end of exposure period.

Table 6. Summary data on bacterial reverse mutation test of 2,6-Bis(1,1-dimethylethyl)-4-ethylphenol (Confirmative examination) [ Non-activation method : -S9] Exp. No. 9048 (115-199)

Compound	Dose (µg/plate)	Revertant colonies per plate [ Mean ± S.D.]									
		TA100	TA1535	WP2uvrA	TA98	TA1537	TA100	TA1535	WP2uvrA	TA98	TA1537
2,6-Bis(1,1-dimethylethyl)-4-ethylphenol	0 a)	121 [ 117 ± 6]	121 [ 119 ± 6]	110 [ 133 ± 2]	19 [ 18 ± 1]	17 [ 17 ± 1]	29 [ 28 ± 1]	22 [ 22 ± 1]	34 [ 34 ± 1]	14 [ 14 ± 1]	15 [ 15 ± 1]
	9.77										
	19.5	124 [ 115 ± 11]	102 [ 102 ± 11]	118 [ 116 ± 10]			22 [ 27 ± 4]	30 [ 30 ± 4]	29 [ 29 ± 4]	8 [ 8 ± 1]	17 [ 17 ± 1]
	39.1	122 [ 113 ± 10]	102 [ 102 ± 10]	116 [ 113 ± 10]			22 [ 23 ± 2]	26 [ 26 ± 2]	22 [ 22 ± 2]	16 [ 16 ± 2]	16 [ 16 ± 2]
	78.1	120 [ 114 ± 6]	114 [ 114 ± 6]	108 [ 108 ± 6]			26 [ 25 ± 3]	27 [ 27 ± 3]	22 [ 22 ± 3]	16 [ 16 ± 3]	16 [ 16 ± 3]
	156	119 [ 117 ± 5]	112 [ 112 ± 5]	121 [ 121 ± 5]	28 [ 28 ± 5]	21 [ 21 ± 5]	24 [ 24 ± 5]	19 [ 19 ± 5]	27 [ 27 ± 5]	17 [ 17 ± 5]	13 [ 13 ± 5]
	313	100 [ 104 ± 4]	107 [ 107 ± 4]	106 [ 106 ± 4]	24 [ 24 ± 4]	19 [ 19 ± 4]	21 [ 21 ± 4]	26 [ 26 ± 4]	21 [ 21 ± 4]	14* [ 14 ± 4]	8* [ 8 ± 4]
	625	116* [ 114 ± 2]	112* [ 112 ± 2]	113* [ 113 ± 2]	24 [ 24 ± 2]	25 [ 25 ± 2]	22 [ 22 ± 2]	22* [ 22 ± 2]	31* [ 31 ± 2]	11* [ 11 ± 2]	14* [ 14 ± 2]

a): Negative control (Dimethyl sulfoxide, 100 µL/plate)

\* : Growth inhibition was observed.



Table 6. Continued

Compound	Dose (µg/plate)	Revertant colonies per plate [ Mean ± S.D.]						
		TAL100	TAL535	WP2uvrA	TA98	TA1537		
2,6-Bis(1,1-dimethylethyl)-4-ethylphenol	1250 +		14 9 11 22 15 16 [ 11 ± 3] [ 18 ± 4]					
	2500 +		15 12 11 22 21 17 [ 13 ± 2] [ 20 ± 3]					
	5000 +		6 9 9 20 20 17 [ 8 ± 2] [ 19 ± 2]					
Positive control		677 699 722 b) [ 699 ± 23]	564 622 556 c) [ 581 ± 36]	155 156 141 b) [ 151 ± 8]	725 699 768 d) [ 731 ± 35]	173 221 167 e) [ 187 ± 30]		

b): AF-2; 2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide, 0.01 µg/plate c): NaN<sub>3</sub>; Sodium azide, 0.5 µg/plate

d): AF-2, 0.1 µg/plate e): 9-AA; 9-Aminoacridine hydrochloride, 80 µg/plate

+ : Visible precipitation was observed at the end of exposure period.

Table 7. Summary data on bacterial reverse mutation test of 2,6-Bis(1,1-dimethylethyl)-4-ethylphenol (Confirmative examination) [Activation method : +S9] Exp. No. 9048 (115-199)

Compound	Dose (µg/plate)	Revertant colonies per plate [Mean ± S.D.]									
		TA100	TA1535	WP2uvrA	TA98	TA1537					
2,6-Bis(1,1-dimethylethyl)-4-ethylphenol	0 a)	117 [ 120 ± 3]	17 [ 12 ± 5]	22 [ 23 ± 5]	26 [ 31 ± 8]	34 [ 28 ± 5]					
	156	96 [ 101 ± 5]	7 [ 9 ± 3]	20 [ 22 ± 2]	36 [ 30 ± 5]	32 [ 32 ± 3]					
	313	84 [ 81 ± 6]	10 [ 10 ± 3]	16 [ 19 ± 5]	28 [ 29 ± 6]	23 [ 22 ± 1]					
	625	108 [ 98 ± 10]	12 [ 14 ± 3]	20 [ 19 ± 2]	31 [ 35 ± 5]	23 [ 19 ± 4]					
	1250 +	95 [ 97 ± 2]	14 [ 10 ± 4]	22 [ 23 ± 4]	28 [ 28 ± 5]	24 [ 20 ± 4]					
	2500 +	87 [ 89 ± 6]	10 [ 11 ± 3]	25 [ 23 ± 2]	34 [ 31 ± 4]	15 [ 16 ± 3]					
5000 +	87 [ 83 ± 5]	7 [ 8 ± 1]	19 [ 19 ± 1]	29 [ 27 ± 3]	12 [ 14 ± 2]						
Positive control	1027 [ 1072 ± 61]	1047 b) [ 1047 ± 61]	338 [ 356 ± 23]	348 c) [ 356 ± 23]	558 [ 527 ± 30]	478 [ 449 ± 36]	409 [ 477 ± 36]	461 e) [ 461 ± 36]	162 [ 177 ± 20]	169 [ 177 ± 20]	200 c) [ 200 ± 20]

a): Negative control (Dimethyl sulfoxide, 100 µL/plate)  
b): 2-AA; 2-Aminoanthracene, 1 µg/plate c): 2-AA, 2 µg/plate d): 2-AA, 10 µg/plate e): 2-AA, 0.5 µg/plate  
+ : Visible precipitation was observed at the end of exposure period.